Ferguson Wellman Capital Management, Inc Novo Nordisk A S Transaction History

Ferguson Wellman Capital Management, Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 Apr 26, 2021	SELL	$67.06 - $75.82 $6.36 Million - $7.19 Million	-94,860 Closed	0 $0
Q4 2020 Feb 04, 2021	SELL	$63.89 - $73.8 $5.88 Million - $6.8 Million	-92,100 Reduced 49.26%	94,860 $6.63 Million
Q3 2020 Oct 13, 2020	BUY	$63.69 - $70.22 $94,261 - $103,925	1,480 Added 0.8%	186,960 $13 Million
Q2 2020 Aug 04, 2020	BUY	$58.54 - $67.94 $233,750 - $271,284	3,993 Added 2.2%	185,480 $12.1 Million
Q1 2020 Apr 21, 2020	BUY	$49.46 - $64.78 $163,218 - $213,774	3,300 Added 1.85%	181,487 $10.9 Million
Q4 2019 Jan 24, 2020	SELL	$49.86 - $58.26 $196,597 - $229,719	-3,943 Reduced 2.16%	178,187 $10.3 Million
Q3 2019 Oct 15, 2019	BUY	$47.54 - $53.43 $316,806 - $356,057	6,664 Added 3.8%	182,130 $9.42 Million
Q2 2019 Jul 16, 2019	BUY	$46.79 - $52.47 $3,696 - $4,145	79 Added 0.05%	175,466 $8.96 Million
Q1 2019 Apr 11, 2019	BUY	$46.36 - $52.63 $324,520 - $368,410	7,000 Added 4.16%	175,387 $9.17 Million
Q4 2018 Jan 16, 2019	BUY	$41.54 - $47.25 $285,379 - $324,607	6,870 Added 4.25%	168,387 $7.76 Million
Q3 2018 Oct 25, 2018	BUY	$46.76 - $51.24 $7.55 Million - $8.28 Million	161,517 New	161,517 $7.61 Million

1,955

320M

5.49M

7.78M

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $240B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

Get notified when there are updates to the investment portfolio of Ferguson Wellman Capital Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Ferguson Wellman Capital Management, Inc with notifications on news.